#### Phenome-wide association study of ovarian cancer identifies common comorbidities and reveals

#### shared genetics with complex diseases and biomarkers

Anwar Mulugeta<sup>1,2&3\*</sup>, Amanda L Lumsden<sup>1&2</sup>, Iqbal Madakkatel<sup>1&2</sup>, David Stacey<sup>1&2</sup>, S.Hong Lee<sup>1,2&4</sup>, Johanna Mäenpää<sup>5&6</sup>, Martin K. Oehler<sup>7&8</sup>, Elina Hyppönen<sup>1&2</sup>

<sup>1</sup>Australian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, Australia

<sup>2</sup>South Australian Health and Medical Research Institute, Adelaide, Australia

<sup>3</sup>Department of Pharmacology and Clinical Pharmacy, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia

<sup>4</sup>UniSA Allied Health & Human Performance, University of South Australia, Adelaide, SA, Australia <sup>5</sup>Faculty of Medicine and Medical Technology, Tampere University, Tampere, Finland

<sup>6</sup>Cancer Centre, Tampere University and University Hospital, Tampere, Finland

<sup>7</sup>Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia <sup>8</sup>Adelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia

#### Short title: MR-PheWAS of ovarian cancer

Funding: This research was funded by Medical Research Future Fund of Australia (MRF2007431).

Competing interests: The authors declare that they have no competing interests.

\*Corresponding author: Dr Anwar Mulugeta Australian Centre for Precision Health, c/o SAHMRI, University of South Australia, Adelaide, Australia, GPO Box 2471, Adelaide SA 5001. Email: anwarmulugeta.gebremichael@unisa.edu.au

### 1 Abstract

Background: Ovarian cancer (OC) is commonly diagnosed among older women who have
comorbidities. This hypothesis-free phenome-wide association study (PheWAS) aimed to identify
comorbidities associated with OC, as well as traits that share a genetic architecture with OC.

5 **Methods**: We used data from 181,203 white British female UK Biobank participants and analysed 6 OC and OC subtype-specific genetic risk scores (OC-GRS) for an association with 889 diseases and 7 43 other traits. We conducted PheWAS and colocalisation analyses for individual variants to identify 8 evidence for shared genetic architecture.

9 Results: The OC-GRS was associated with 10 diseases, and the clear cell OC-GRS was associated 10 with five diseases at the FDR threshold ( $p = 5.6 \times 10^{-4}$ ). Mendelian randomisation analysis (MR) 11 provided robust evidence for the association of OC with higher risk of "secondary malignant 12 neoplasm of digestive systems" (OR 1.64, 95% CI 1.33, 2.02), "ascites" (1.48, 95% CI 1.17, 1.86), 13 "chronic airway obstruction" (1.17, 95% CI 1.07, 1.29), and "abnormal findings on examination of 14 the lung" (1.51, 95% CI 1.22, 1.87). Analyses of lung spirometry measures provided further support 15 for compromised respiratory function. PheWAS on individual OC variants identified five genetic 16 variants associated with other diseases, and seven variants associated with biomarkers (all,  $p \le 4.5 \times 10^{-10}$ 17 <sup>8</sup>). Colocalisation analysis identified rs4449583 as the shared causal variant for OC and seborrheic 18 keratosis.

19 Conclusions: OC is associated with digestive and respiratory comorbidities. Several variants 20 affecting OC risk were associated with other diseases and biomarkers, with this study identifying a 21 novel genetic locus shared between OC and skin conditions.

- 23 **Keywords:** Ovarian cancer, comorbidities, *TERT*, PheWAS, UK Biobank
- 24

## 25 1. Introduction

26	Ovarian cancer (OC) is a notorious gynaecological disorder, with only 44% of affected women
27	surviving 5 years. <sup>1</sup> Reducing mortality associated with OC remains a challenge as the poor
28	understanding of the origin and biology of the disease limits opportunities to prevention, and the
29	disease is typically detected at an advanced stage when treatment options are limited. <sup>2</sup> Approximately
30	90% of OC are epithelial OC and arise from epithelial cells, predominantly of the fallopian tube and
31	endometrium. <sup>2-4</sup> Epithelial OC can be further classified into serous, endometroid, clear cell, and
32	mucinous subtypes, based on their histological characteristics <sup>3</sup> and indeed, the pathogenesis, disease
33	progression, and risk factors are known to vary between OC subtypes. <sup>3, 5</sup> Given that OC is commonly
34	diagnosed in women aged 50 years and above, <sup>6</sup> many patients present with at least one comorbidity,
35	which can influence treatment decisions, impact prognosis and affect overall survival. <sup>7, 8</sup> Hence,
36	exploring the associations between OC and comorbidities, along with understanding potential shared
37	genetic links between OC and other traits, may offer insights into the underlying etiology of the
38	disease. Such insights could lead to facilitating earlier detection and better management of the disease.
39	Phenome-wide association study (PheWAS) is a powerful approach for testing the association of
40	genetic variants or their risk score with a broad range of phenotypes and disease outcomes. <sup>9</sup> This
41	approach offers the advantage of being hypothesis-free, allowing it to explore numerous associations
42	without constraints of the number of outcomes. Consequently, PheWAS has the potential to unveil
43	novel genetic associations with diseases. <sup>9</sup> In this study we use data on genetic OC risk variants and
44	889 disease outcomes from 181,203 female UK Biobank participants to identify comorbidities and
45	clinical characteristics associated with the genetic risk of OC. We test for evidence of a direct
46	association between OC and possible comorbidities using Mendelian randomisation (MR), an
47	approach less susceptible to confounding and reverse causation, <sup>10</sup> and extend these analyses to focus
48	on the genetic risk reflecting distinct histological OC subtypes. We also use the PheWAS approach to
49	explore each OC associated variant individually, which can provide evidence for shared genetic
50	contributions, and provide insight into the underlying disease mechanisms.

51

#### 52 2. Methods

## 53 2.1. Study population

54 UK Biobank is a prospective cohort study of half a million participants with rich phenotype and 55 genotype data collected across 22 centres in England, Scotland, and Wales. The baseline assessment was conducted between 2006 and 2010 when the participants were aged between 37 to 73 years.<sup>11</sup> A 56 57 wide range of data was collected, including sociodemographic information, lifestyle factors, physical 58 measures, blood and urine samples for biomarker and genetic profiling, with continuing updates 59 through follow-up assessments and linkage with electronic health records and death registrations.<sup>11</sup> 60 For the primary analyses in this study, we restricted the sample to 181,203 female participants who 61 were of white British ancestry and were not genetically related (Figure S1) and included male 62 participants in sensitivity analyses (n = 156,220). The study was conducted under UK Biobank 63 application number 89630. UK Biobank obtained informed consent from all participants to collect and 64 use linked data for future research use, and the UK Biobank study has ethical approval from the 65 National Information Governance Board for Health and Social Care and Northwest Multicenter 66 Research Ethics Committee (11/NW/0382).

67

#### 68 2.2. Disease outcomes and biomarkers

We used International Classification of Diseases (ICD version 9 and 10) codes from hospital episode statistics and death registrations to identify disease outcomes (Supplementary methods). We mapped ICD-9/10 codes to phecodes, which are composite groupings reflecting clinically relevant disease outcomes.<sup>12</sup> We defined individuals with the phecode-of-interest as cases, and those without the phecode-of-interest, or any other phecodes from the same disease category as controls (Supplementary methods).<sup>12, 13</sup> We included all phecodes with at least 200 cases in our analyses,<sup>14</sup> resulting in 889 phecodes from 18 disease categories (Table S1).

76 We also included 30 serum and four urine biomarkers, which are commonly used for the diagnosis

and monitoring of chronic diseases, as outcome measures (Supplementary methods). Additional

analyses were conducted against selected physiological characteristics (namely body mass index

- (BMI), body fat percentage (BFP), basal metabolic rate (BMR), blood pressures, and measures of
- 80 lung function (spirometry) due to their known associations with comorbidity risks. The spirometry
- 81 measures included forced expiratory volume in 1-second (FEV1), forced vital capacity (FVC),
- 82 FEV1/FVC ratio, and peak expiratory flow (PEF).

### 83 2.3. Genetic variants and genetic risk score

- 84 We selected 35 genetic variants associated with OC from previous genome-wide association studies
- 85 (GWAS), including the 12 novel variants identified in the most recent GWAS<sup>15</sup> and 23 variants

identified in earlier GWASs (minor allele frequency  $\geq 1.4\%$ , Table S2, Figure S2).<sup>16-23</sup> We

- 87 constructed the genetic risk score (GRS) using 31 genetic variants after excluding one variant that had
- 88 no proxy at  $r^2 \ge 0.8$  (rs555025179), and three variants (rs12131772, rs4691139, and rs12938171) that

89 were not replicated in the recent GWAS,<sup>15</sup> which we extracted from the imputed genotype UK

- 90 Biobank data <sup>24</sup> (Table S2). The GRS was constructed for each individual by summing the weighted
- 91 number of OC risk-associated variants, with the weight taken from the recent OC GWAS.<sup>15</sup> We also
- 92 constructed risk scores for each OC subtype (Supplementary methods).

#### 93 **2.4. Statistical analyses**

94 We conducted phenome-wide analyses using R-package PheWAS<sup>25</sup> which allowed us to fit logistic

95 regression (889 disease outcomes) or linear regression (43 biomarkers/physiological characteristics)

against the OC GRS with all models adjusted for age, assessment centre, type of genotyping array,

97 birth location, and 40 principal components (Figure S2). We repeated the phenome-wide analyses for

98 each OC subtype GRS to identify subtype-specific disease associations, and further, conducted the

99 analyses in male participants to understand whether the OC – disease associations involve non-sex-

100 specific mechanistic pathways.

101	The phenome-wide association signals that passed the FDR threshold (p $< 5.6 \times 10^{-4}$ for the diseases
102	and p <0.02 for the biomarkers and physiological measures, Supplementary methods) were taken
103	forward to MR analysis to examine evidence for direct association with OC. We used two-sample MR
104	approach where variant – OC association estimates were taken from the recent OC GWAS, <sup>15</sup> and the
105	variant-outcome association estimates were from the UK Biobank. MR analyses were conducted on
106	signals associated with the overall OC GRS or with any subtype-based GRSs. We used inverse
107	variance weighted (IVW) MR <sup>26</sup> as the primary method and conducted sensitivity analyses using
108	weighted median, <sup>27</sup> weighted mode, <sup>28</sup> MR-PRESSO, <sup>29</sup> and MR-Egger, <sup>30</sup> with each method working on
109	different pleiotropic assumptions (Supplementary methods). We tested for horizontal pleiotropy using
110	MR-Egger intercept, MR-PRESSO outlier and distortion tests, leave-one-out and leave-block-out
111	methods (Table S3, Supplementary methods). MR analyses were repeated excluding the OC cases. To
112	test the MR assumption that the genetic instrument should not be associated with potential
113	confounding factors, we explored the association between the OC GRSs and age, education,
114	Townsend deprivation index, BMI, physical activity, and alcohol consumption (Supplementary
115	methods, Table S4).
116	We repeated the phenome-wide analyses for each OC genetic variant individually, again conducting
117	analyses separately for men. We assessed the novelty of the PheWAS findings by checking the
118	reported associations in the GWAS Catalog. We considered a locus-trait association as potentially
119	novel if neither the lead variant nor any variant in linkage disequilibrium (LD) with the lead variant
120	(with an $r^2 \ge 0.1$ ) had previously been reported to be associated with the same or related traits. For
121	those potentially novel associations, we conducted a follow-up colocalisation analysis using the
122	HyPrColoc (Hypothesis Prioritization in multi-trait Colocalisation) tool to assess whether there is
123	evidence of shared causal genetic variants between pairs of traits. <sup>31</sup> We considered a posterior
124	probability of full colocalisation (PPFC) >0.64 as indicative of shared genetic etiology between these
125	traits (Supplementary methods). <sup>31</sup>

126 Statistical analyses were performed using STATA SE version 17.1, R version 4.2.1 and PLINK2.<sup>32</sup>

## 127 **3. Results**

- 128 We included up to 181,203 female white British participants in the primary analyses, of whom 1,863
- 129 (1.3%) had been diagnosed with OC (Table 1). The prevalence of OC was higher among participants
- 130 who were older, obese, never drinkers of alcohol, and those with poor general health status at the
- 131 baseline (for all, prevalence  $\geq$ 1.2%, and p  $\leq$ 0.03). The OC risk GRS was normally distributed and
- 132 associated with OC as expected, with stronger association in the highest compared to the lowest
- 133 genetic risk group (F-statistics =23.7, p = $4.4 \times 10^{-16}$ , Figure S3). No associations were found between
- 134 the risk scores and potential confounders after correction for multiple testing (Table S5).

### 135 **3.1. Phenome-wide-based Mendelian randomisation**

- 136 We investigated 889 disease outcomes from 18 disease categories in the phenome-wide analyses. We
- 137 observed significant associations between the OC GRS and 10 diseases from four disease categories
- 138 (neoplasms, digestive, respiratory and genitourinary diseases) after FDR correction ( $p \le 5.6 \times 10^{-4}$ ).
- 139 The top signals were for "cancer of the female genital organs", "malignant neoplasm of ovary and
- 140 other uterine adnexa", and "malignant neoplasm of the ovary", which confirms the 'relevance
- 141 assumption' of the MR approach<sup>10</sup> (Supplementary methods) for using the GRS as instrument for OC
- 142 (for all,  $p \le 4.8 \times 10^{-4}$ , Figure 1, Panel A). The GRS was also associated with higher risk of other
- 143 cancers and abnormal growths including "secondary malignant neoplasm of digestive systems",
- 144 "lipoma, including lipoma of skin and subcutaneous tissue" ( $p \le 3.9 \times 10^{-4}$ ), and "ovarian cyst" (p = 6.0
- 145  $\times 10^{-5}$ ). In addition, we identified associations with respiratory outcomes including "chronic airway
- 146 obstruction" and "abnormal findings on examination of the lungs", and with the digestive system
- 147 outcome, "ascites" ( $p \le 3.2 \times 10^{-4}$ ).
- 148 In analyses using GRSs for specific OC subtypes (Figure 1 Panel B and C), the clear cell OC GRS
- 149 was associated with additional diseases and increased risks such as "benign neoplasm of uterus", and
- 150 "uterine leiomyoma", "disorders of menstruation", "gram negative septicemia", and "postoperative
- 151 infection" (for all,  $p \le 2.3 \times 10^{-4}$ ). Overall, in addition to overall OC-related outcomes, 12 other
- 152 disease outcomes were associated with at least one form of the OC GRS. Notably, none of these
- 153 associations were detected when we repeated the phenome-wide analyses among men (Figure S4).

154 Additionally, our phenome-wide analyses on 43 quantitative traits, which included serum and urine

biomarkers and physiological measures, identified an association of OC GRS with 13 traits.

156 Furthermore, we found an additional 11 traits associated with at least one subtype of OC GRS (Figure157 S5).

158 We conducted two-sample MR analyses on 12 disease outcomes identified in the PheWAS. For each 159 outcome, evidence of causality was identified for at least one type of OC (Figure 2). We found robust 160 evidence supporting the association between a higher genetic liability of OC and an increased risk of 161 "secondary malignant neoplasm of digestive systems" (OR 1.64, 95% CI 1.33, 2.023), "ascites" (1.48, 162 95% CI 1.17, 1.86), "chronic airway obstruction" (1.17, 95% CI 1.07, 1.29), and "abnormal finding 163 on the examination of the lungs" (1.51, 95% CI 1.22, 1.87). These associations were further supported 164 by other MR methods (Figure S6). Additionally, we observed an association between a higher genetic 165 liability of OC and an increased risk of "ovarian cyst" (1.23, 95% CI 1.04, 1.46), as well as "lipoma 166 including lipoma of skin and subcutaneous tissues" (1.31, 95% CI 1.06, 1.61). Notably, the weighted 167 median and weighted mode MR methods specifically supported the association with "lipoma of the 168 skin and subcutaneous tissues" (Figure S6). There was some evidence supporting the association 169 between OC and higher risk of "postoperative infection" and "gram-negative septicemia", identified 170 in the phenome-wide analyses on clear cell OC. However, these associations were observed only in 171 the IVW and MR-PRESSO MR methods (Figure S6). In the MR analyses on OC subtypes (Figure 2), 172 serous, endometrioid and clear cell OC were all associated with "secondary malignant neoplasm of 173 digestive systems" and "ascites". Serous and endometrioid subtypes showed evidence of effects on 174 the respiratory outcomes. While the case numbers were lower for mucinous OC, this histotype was the 175 only one to show evidence of an association with "lipoma of the skin and subcutaneous tissues" as 176 evidenced by all MR methods. However, mucinous OC was not associated with any of the other 177 outcomes (Figure S6). The clear cell subtype was associated with "ovarian cyst", "benign uterine 178 neoplasms", "uterine leiomyoma", and "disorders of menstruation". Both serous and clear cell 179 subtypes increased the risk of postoperative infection traits, with clear cell also increasing risk for 180 "gram negative septicemia" (Figure 2 & Figure S6). We conducted analyses also excluding all known

181 OC cases, and associations with "secondary malignant neoplasm of digestive systems" and "ascites" 182 were attenuated, while estimates for all other outcomes were generally similar to the main findings 183 (Figure S7). The MR-Egger intercept did not suggest evidence of pleiotropy for most associations, 184 except for the association between serous OC and "postoperative infections" (pintercept =0.01), which 185 therefore should be cautiously interpreted. No evidence of pleiotropy was found using the MR-186 PRESSO outlier test and leave-one-out analysis (Figure S8). The estimates obtained from leave-187 block-out analyses were broadly consistent with the overall findings (Figure S9). 188 MR analyses on serum biomarkers and physiological measures supported the association of 189 OC with lower FVC, endometrioid OC with lower oestradiol, clear cell OC with lower total 190 cholesterol, low density lipoprotein (LDL) cholesterol, and apolipoprotein B (ApoB), and mucinous 191 OC with higher gamma glutamyltransferase (GGT) and alanine aminotransferase (ALT) and lower 192 creatinine levels (Figure S10). Analyses excluding all known OC cases, provided generally similar 193 estimates to the main findings (Figure S11). For these identified associations, we did not find any 194 evidence of pleiotropy based on the MR-Egger intercept tests ( $p_{intercept} \ge 0.13$ ) and leave-one-out 195 analyses. MR analyses on men provided evidence for a genetic association between mucinous OC and 196 ALT (Figure S10).

197 **3.2. Shared genetic architecture** 

198 In the phenome-wide analyses assessing associations with individua OC risk-associated genetic

199 variant, five variants were associated with at least one of 15 (11 distinct) disease outcomes (all,  $p \le 4.5$ 

 $200 \times 10^{-8}$ , Figure 3, Table S6), and seven variants were associated with at least one of 22 biomarkers and

201 physiological measures (Figure S12). Some of these associations were also observed in the analyses

among men, with selected OC variants affecting conditions of the male genital organs (Figure 3,

203 Table S6 and Figure S12, Supplementary Results). To ensure the novelty of our findings, we

204 extensively checked the GWAS Catalog for any reports of associations with the identified (or related)

205 diseases involving the lead or proxy variants ( $r^2 \ge 0.1$ ). As a result, we uncovered potential novel

associations between the OC risk-increasing allele from the TERT locus (rs10069690-T) and a lower

risk of "seborrheic keratosis" (0.79, 95% CI 0.72, 0.87), in females, with similar a finding observed in

- 208 males. To further validate the associations, we conducted colocalisation analysis at the *TERT* locus
- 209 (LD block of chr5:982252 to chr5:2132442, human genomic build of hg19) and identified rs4449583
- as the candidate causal variant explaining around 70% of 0.9239 PPFC for OC-"seborrheic keratosis"
- 211 (Figure 4). This variant is also strongly associated with OC in the Phelan OC GWAS<sup>15</sup> ( $p = 7.8 \times 10^{-12}$ ),
- and in LD with the index variant from this GWAS (rs7705526,  $r^2 = 0.784$ ) and with the lead variant in
- 213 the primary discovery OC GWAS<sup>22</sup> (rs100699690,  $r^2 = 0.432$ , Supplementary Methods). The
- association between the GPX6 locus and "disorders of iron metabolism" and "celiac disease" are
- 215 potentially novel, although colocalisation analysis did not suggest that OC share the same causal
- 216 variants with these two diseases (Figure S13). On the contrary, we identified independent potential
- 217 causal genetic variant for each "disorders of iron metabolism" (rs34409925,  $r^2 = 0.207$  with
- 218 rs6456822) and "celiac disease" (rs3131101,  $r^2 = 0.049$  with rs6456822) in further conditional analysis
- 219 (Figure S13).

## 221 **4.** Discussion

222	In this large-scale phenome-wide study, we aimed to explore comorbidity risks associated with OC,
223	with additional analyses to identify subtype-specific associations based on genetic variants reflecting
224	different OC histological types. We found evidence supporting a possible causal association between
225	OC and 12 disease outcomes, including "secondary malignant neoplasm of the digestive system",
226	"ascites", and respiratory disorders. We also identified some additional subtype-specific associations,
227	including clear cell OC showing links with "gram-negative septicemia", "uterine leiomyoma" and
228	"disorders of menstruation", and mucinous OC with "lipoma of the skin and subcutaneous tissue".
229	Analyses using 43 biomarkers also identified an association with seven biomarkers and these findings,
230	along with those from disease analyses, may have important implications for improving the clinical
231	management of patients with OC. Moreover, our exploration of each OC-risk increasing variant in the
232	PheWAS revealed a set of traits that are genetically shared with OC. This analysis not only confirmed
233	previous GWAS findings but also shed light on novel associations deserving further investigations.
234	OC is the leading cause of cancer-related ascites in females. <sup>33</sup> Our MR-PheWAS study revealed
235	genetic evidence linking ascites to OC across all subtypes except mucinous OC, which is consistent
236	with the fact that over one-third of women with OC develop ascites during their lifetime. <sup>33, 34</sup> Ascites
237	is commonly considered a sign of advanced OC, <sup>35</sup> and in line with this, the evidence for an
238	association in our analyses was removed after excluding known OC cases. In patients with OC, the
239	presence of ascites commonly indicates metastasis to peritoneal surfaces and reflects the extent of the
240	disease. <sup>36</sup> Our study further established a causal association between OC and "secondary malignant
241	neoplasms of the digestive system", indicating intra-abdominal dissemination of the tumour. Again,
242	this association was sensitive to the inclusion of known OC cases in our analyses, and is likely to
243	explained by a metastasis of the OC affecting the gastrointestinal tract or, potentially, a new
244	synchronous gastrointestinal cancer.
245	OC has also been linked to respiratory complications. <sup>37, 38</sup> Our study provides additional supporting

evidence for this association, specifically linking OC to an increased risk of "chronic airway

247 obstruction" and "abnormal lung examinations". The findings were further supported by spirometry 248 measures, which showed a significant association between a higher genetic liability to OC and lower 249 FVC. While in women with OC lowering of lung function may follow from malignant pleural effusion and tumour metastasis to the pleura<sup>37</sup> or complications related to surgical procedures,<sup>38</sup> in our 250 251 analysis the association with lung disease remained when OC cases were excluded, and the 252 spirometric association was seen both in women and in men, which may indicate a more profound 253 biological link. 254 OC as reflected by our genetic study arises from the epithelium of the ovaries, endometrium and 255 fallopian tubes, and while most of the lung also consists of epithelium, a direct link has not been well 256 established. Interestingly, colocalisation analyses in our study also suggested that disorder of skin 257 condition (seborrheic keratosis) shared a genetic locus (TERT, encoding the enzyme, telomerase) with 258 OC, highlighting potential shared pathomechanisms involving the epithelium, and implicating telomerase function in the opposing risks of OC and the skin disorder.<sup>39,40</sup> 259 260 Debulking cytoreductive surgery is the standard procedure for advanced OC. It involves the surgical 261 removal of female reproductive organs such as the ovaries, fallopian tubes, uterus, as well as omentum and organs of the digestive system, such as the bowel, depending on the stage of OC.<sup>41</sup> The 262 263 invasive nature of this intervention,<sup>41</sup> combined with compromised immune system function resulting 264 from the disease,<sup>42</sup> may explain the observed association between OC and "postoperative infection" 265 and "gram-negative septicemia". It is important to note that these associations were predominantly 266 observed in clear cell OC, which has also been associated with "benign neoplasms of the uterus", 267 "uterine leiomyoma", and "disorders of menstruation". The presence of these conditions, which 268 primarily involve the uterine tissue, could reflect the well-established association between 269 endometriosis and clear cell OC.<sup>43, 44</sup> Our study also identified OC subtype specific associations

270 between mucinous OC and "lipoma of the skin and subcutaneous tissue". Regarding the biomarkers,

271 endometroid OC was associated with lower serum oestradiol level, clear cell OC was associated with

272 lower serum total cholesterol, LDL cholesterol, and ApoB, while mucinous OC was associated with

273 higher serum GGT and ALT as well as lower creatinine levels. These findings suggests that

274 comorbidities and selected biomarkers may play a role in identifying and characterising different

subtypes of OC.

276	Beyond the causal link between OC and disease outcomes and biomarkers, genetic variants
277	contributing to a higher risk of OC may also be associated with other diseases and biomarkers. The
278	ABO locus is a well-known pleiotropic locus with established associations with cardiovascular and
279	cerebrovascular traits. <sup>45-50</sup> Our study confirmed these existing findings, as we also observed
280	associations between the ABO variant and conditions such as "pulmonary heart disease",
281	"thrombophlebitis", and "other disorders of circulatory system". Additionally, we confirmed the
282	association between ABO with many cardiometabolic biomarkers, including associations with markers
283	of glucose and liver metabolism, confirming the highly pleiotropic nature of this variant. <sup>51</sup>
284	Our study identified a significant association between the GPX6 variant (rs6456822) and a lower risk
285	of disorders related to iron metabolism, which is a critical component of overall health. <sup>52</sup> However,
286	while the lead variant rs6456822 showed this association, our colocalisation analysis identified an
287	independent potential causal variant, rs34409925, for "disorders of iron metabolism". We also found
288	another potential causal variant at the GPX6 locus, rs3131101, for "celiac disease". The OC lead
289	variant rs6456822 was also associated with total protein levels in women, as well as with SHBG
290	levels in men. Our study also identified a potential novel association between the TERT locus
291	(rs10069690) and "seborrheic keratosis". The follow up colocalisation analysis strengthened the
292	shared genetic structures between this skin condition and OC, further suggesting that rs444583 may
293	be a causal variant. Importantly, we confirmed previous associations of the TERT variant with uterine
294	leiomyoma <sup>44, 53</sup> and total protein levels in women <sup>49, 51</sup> , as well as with prostate cancer in men. <sup>54</sup> Our
295	findings highlight the value of using PheWAS for validating previous GWAS findings and identifying
296	potential novel variants for multiple traits including diseases and biomarkers that never been tested
297	before. <sup>55</sup>

Our study has a number of strengths. Firstly, it is the largest (n = 181,203) and most comprehensive study to date that examines the health risks associated with a higher genetic susceptibility to OC.

300 Secondly, by including OC subtypes in our analysis, our study can identify subtype-specific 301 comorbidities, supporting more effective treatment and management. Lastly, our study extended the 302 phenome-wide analyses to each OC-risk-increasing variant. This approach enables us to confirm 303 previously identified variant-disease associations and also identify potential novel associations, thus 304 providing a more comprehensive understanding of the shared genetic links between OC and other 305 diseases. Further incorporation of colocalisation analysis is another strength of this study. It provided 306 evidence of a shared genetic locus (TERT) between OC and "seborrheic keratosis", and identified a 307 potential novel causal variant, rs4449583, for this skin condition. 308 Our study also has some limitations. To ensure the validity of MR, the genetic instrument used must 309 be associated with the risk factor (in our case, OC), not associated with the confounders of the risk

310 factor-outcome association, and not influence the outcome except through its association with the risk 311 factor. While we used a genetic instrument that associates with OC and conducted our analysis on a

311 factor. While we used a genetic instrument that associates with OC and conducted our analysis on a

312 white-European population while adjusting for confounding factors, we cannot rule out the absence of

313 horizontal pleiotropic effects, which will affect interpretation and can bias the MR estimates.<sup>56</sup> To

314 address this concern, we repeated our analysis in men to further verify whether the association we

315 observed is genuinely related to OC or a reflection of genetic variants indicating shared mechanistic

316 pathways between both men and women. Another potential limitation of our study is that the UK

317

320

318 collider bias due to the "healthy volunteer" selection bias.<sup>58</sup> However, the modest collider bias in the

Biobank participants are relatively healthy compared to the general population,<sup>57</sup> introducing to

319 context of MR is less likely to affect MR results significantly when the selection into the study was

321 associations in our study provides support for the validity of our results despite this limitation. It could

not strongly influenced by the risk factor.<sup>58</sup> Furthermore, the presence of biologically plausible causal

322 be noted as a limitation of our study that our investigation into comorbidities associated with OC was

323 primarily conducted in a population predominantly not diagnosed with OC. However, sensitivity

324 analyses excluding all known OC cases confirmed that the associations with OC complications

325 relating to ascites and gastrointestinal metastases are related to the disease *per se*, while the other

- 326 observed disease and trait associations may reflect earlier stages of OC development or other
- 327 underlying biological differences.
- 328 In conclusion, our study identified robust associations between OC and comorbidities related to the
- 329 digestive and respiratory systems. Furthermore, we observed specific robust associations for different
- 330 subtypes of OC, such as "gram-negative septicemia", 'uterine leiomyoma" and "disorders of
- 331 menstruation" for clear cell OC, and lipoma for mucinous OC. Interestingly, our study points to a
- 332 shared genetic architecture between OC and a skin condition, leading to a discovery of a novel variant
- 333 which merits further investigation.

335	Funding
336	This study was supported by Medical Research Future Fund of Australia (MRFF), grant number
337	2007431.
338	
339	Competing interests
340	The authors declare that they have no competing interests.
341	
342	Acknowledgements
343	The authors are very grateful to the UK Biobank and UK Biobank Participants.
344	
345	Authors' contributions
346	AM conceived the study with EH, conducted the analysis, and wrote the first draft. E.H. supervised
347	the study and advised on analyses. DS conducted the colocalisation analysis using summary results
348	generated by AM. All authors interpreted the results, revised the manuscript, and approved the final
349	manuscript.
350	
351	Ethical approval
352	The study was conducted under UK Biobank application number 89630. UK Biobank study has
353	ethical approval from the National Information Governance Board for Health and Social Care and
354	Northwest Multicenter Research Ethics Committee (11/NW/0382).
355	Consent to participate
356	UK Biobank obtained informed consent from all participants to collect and use linked data for future
357	research use.

## 358 Data availability

- 359 This research has been conducted using the UK Biobank Resource under Application Number 89630.
- 360 The data and analytical code that support the findings of this study are available on application to the
- 361 UK Biobank (<u>https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access</u>).

# 363 **<u>References</u>**

364	1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R,
365	Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin
366	2014;64:252-71.
367	2. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a
368	proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
369	3. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the
370	size of the problem. Best practice & research. Clinical obstetrics & gynaecology
371	2006;20:207-25.
372 373	4. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, et al. Transformation of the fallopian tube
374	secretory epithelium leads to high-grade serous ovarian cancer in Brca; Tp53; Pten models.
3/5	Cancer Cell 2013;24: /51-65.
376 377	5. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. The Lancet 2019;393:1240-53.
378	6. Zhang S, Cheng C, Lin Z, Xiao L, Su X, Zheng L, Mu Y, Liao M, Ouyang R, Li
379	W, Ma J, Cai J, et al. The global burden and associated factors of ovarian cancer in 1990-
380	2019: findings from the Global Burden of Disease Study 2019. BMC public health
381	2022;22:1455.
382	7. Jiao YS, Gong TT, Wang YL, Wu QJ. Comorbidity and survival among women
383	with ovarian cancer: evidence from prospective studies. Scientific reports 2015;5:11720.
384	8. Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on
385	chemotherapy use and outcomes in solid tumors: a systematic review. Journal of clinical
386	oncology : official journal of the American Society of Clinical Oncology 2011;29:106-17.
387	9. Bush WS, Oetjens MT, Crawford DC. Unravelling the human genome-phenome
388	relationship using phenome-wide association studies. Nature Reviews Genetics 2016;17:129-
389	45.
390	10. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation
391	studies: a guide, glossary, and checklist for clinicians. BMJ 2018;362:k601.
392	11. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott
393	P, Green J, Landray M, Liu B, Matthews P, et al. UK Biobank: an open access resource for
394	identifying the causes of a wide range of complex diseases of middle and old age. PLOS
395	Medicine 2015;12:e1001779.
396	12. Wei WQ, Bastarache LA, Carroll RJ, Marlo JE, Osterman TJ, Gamazon ER, Cox
397	NJ, Roden DM, Denny JC. Evaluating phecodes, clinical classification software, and ICD-9-
398	CM codes for phenome-wide association studies in the electronic health record. PLoS One
399	2017;12:e0175508.
400	13. King C, Mulugeta A, Nabi F, Walton R, Zhou A, Hyppönen E. Mendelian
401	randomization case-control PheWAS in UK Biobank shows evidence of causality for
402	smoking intensity in 28 distinct clinical conditions. EClinicalMedicine 2020;26:100488.
403	14. Verma A, Bradford Y, Dudek S, Lucas AM, Verma SS, Pendergrass SA, Ritchie
404	MD. A simulation study investigating power estimates in phenome-wide association studies.
405	BMC bioinformatics 2018;19:120.
406	15. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ,
407	Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Jr., et al. Identification of 12
408	new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet
409	2017;49:680-91.

410 16. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-411 Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dörk T, Goode EL, et al. A genome-412 wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat 413 Genet 2009;41:996-1000. 414 17. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, 415 Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, et al. A 416 genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 417 8q24. Nat Genet 2010;42:874-9. 418 18. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-419 Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, et al. Common variants at 19p13 are 420 associated with susceptibility to ovarian cancer. Nat Genet 2010;42:880-4. 421 19. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, 422 Besenbacher S, Lundin P, Stacey SN, Gudmundsson J, Magnusson OT, le Roux L, et al. 423 Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011;43:1104-7. 424 20. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy 425 P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, et al. Genome-wide 426 association study in BRCA1 mutation carriers identifies novel loci associated with breast and 427 ovarian cancer risk. PLoS genetics 2013;9:e1003212. 428 21. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley 429 M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, et al. GWAS meta-analysis and 430 replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013;45:362-431 70, 70e1-2. 432 22. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson 433 K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, et al. Identification of six new 434 susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 2015;47:164-71. 435 23. Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley 436 J, Chen X, Spindler TJ, Aben KK, Anton-Culver H, et al. Genome-wide significant risk 437 associations for mucinous ovarian carcinoma. Nat Genet 2015;47:888-97. 438 24. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, 439 Vukcevic D, Delaneau O, O'Connell J, Cortes A, Welsh S, et al. The UK Biobank resource 440 with deep phenotyping and genomic data. Nature 2018;562:203-09. 441 25. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools 442 for phenome-wide association studies in the R environment. Bioinformatics 2014;30:2375-443 76. 444 26. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A 445 framework for the investigation of pleiotropy in two-sample summary data Mendelian 446 randomization. Stat Med 2017;36:1783-802. 447 27. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in 448 mendelian randomization with some invalid instruments using a weighted median estimator. 449 Genet Epidemiol 2016;40:304-14. 450 28. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data 451 Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 452 2017;46:1985-98. 453 29. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal 454 pleiotropy in causal relationships inferred from Mendelian randomization between complex 455 traits and diseases. Nat Genet 2018;50:693-98. 456 30. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson 457 JR. Assessing the suitability of summary data for two-sample Mendelian randomization 458 analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol 459 2016;45:1961-74.

460	31. Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, Howson JMM. A
461	fast and efficient colocalization algorithm for identifying shared genetic risk factors across
462	multiple traits. Nature communications 2021;12:764.
463	32. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-
464	generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015;4:7.
465	33. Parsons SL, Lang MW, Steele RJC. Malignant ascites: a 2-year review from a
466	teaching hospital. European Journal of Surgical Oncology (EJSO) 1996;22:237-39.
467	34. Avantunde AA, Parsons SL. Pattern and prognostic factors in patients with
468	malignant ascites: a retrospective study. Annals of Oncology 2007;18:945-49.
469	35. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer:
470	new avenues for therapy and research. Nat Rev Cancer 2013;13:273-82.
471	36. Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for
472	targeted therapy-based translational research. Front Oncol 2013;3:256.
473	37. Porcel JM, Diaz JP, Chi DS. Clinical implications of pleural effusions in ovarian
474	cancer. Respirology 2012;17:1060-7.
475	38. Xu M, Zhang W, Gao C, Zhou Y, Xie Y. Postoperative pulmonary complications
476	and outcomes in cytoreductive surgery for ovarian cancer: a propensity-matched analysis.
477	BMC anesthesiology 2022;22:120.
478	39. Buckingham EM, Klingelhutz AJ. The role of telomeres in the ageing of human
479	skin. Experimental Dermatology 2011;20:297-302.
480	40. Chen B, Yan Y, Wang H, Xu J. Association between genetically determined
481	telomere length and health-related outcomes: A systematic review and meta-analysis of
482	Mendelian randomization studies. Aging Cell 2023;22:e13874.
483	41. Pomel C, Jeyarajah A, Oram D, Shepherd J, Milliken D, Dauplat J, Reynolds K.
484	Cytoreductive surgery in ovarian cancer. Cancer Imaging 2007;7:210-5.
485	42. Cubillos-Ruiz Juan R, Silberman Pedro C, Rutkowski Melanie R, Chopra S,
486	Perales-Puchalt A, Song M, Zhang S, Bettigole Sarah E, Gupta D, Holcomb K, Ellenson
487	Lora H, Caputo T, et al. ER Stress Sensor XBP1 Controls Anti-tumor Immunity by
488	Disrupting Dendritic Cell Homeostasis. Cell 2015;161:1527-38.
489	43. Mortlock S, Corona RI, Kho PF, Pharoah P, Seo JH, Freedman ML, Gayther SA,
490	Siedhoff MT, Rogers PAW, Leuchter R, Walsh CS, Cass I, et al. A multi-level investigation
491	of the genetic relationship between endometriosis and ovarian cancer histotypes. Cell Rep
492	Med 2022;3:100542.
493	44. Gallagher CS, Mäkinen N, Harris HR, Rahmioglu N, Uimari O, Cook JP, Shigesi
494	N, Ferreira T, Velez-Edwards DR, Edwards TL, Mortlock S, Ruhioglu Z, et al. Genome-wide
495	association and epidemiological analyses reveal common genetic origins between uterine
496	leiomyomata and endometriosis. Nature communications 2019;10:4857.
497	45. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss
498	M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, et al. Large-scale association
499	analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet
500	2011;43:333-8.
501	46. Lindström S, Brody JA, Turman C, Germain M, Bartz TM, Smith EN, Chen MH,
502	Puurunen M, Chasman D, Hassler J, Pankratz N, Basu S, et al. A large-scale exome array
503	analysis of venous thromboembolism. Genet Epidemiol 2019;43:449-57.
504	47. Klarin D, Busenkell E, Judy R, Lynch J, Levin M, Haessler J, Aragam K, Chaffin
505	M, Haas M, Lindström S, Assimes TL, Huang J, et al. Genome-wide association analysis of
506	venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular
507	disease. Nat Genet 2019;51:1574-79.
508	48. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman Å K,
509	Wilk JB, Morley MP, Chaffin MD, Helgadottir A, Verweij N, et al. Genome-wide

510 association and Mendelian randomisation analysis provide insights into the pathogenesis of 511 heart failure. Nature communications 2020;11:163. 512 49. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, 513 Konuma T, Yamamoto K, Akiyama M, Ishigaki K, Suzuki A, et al. A cross-population atlas 514 of genetic associations for 220 human phenotypes. Nat Genet 2021;53:1415-24. 515 50. Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, Gagnon 516 DR, DuVall SL, Li J, Peloso GM, Chaffin M, Small AM, et al. Genetics of blood lipids 517 among ~300,000 multi-ethnic participants of the Million Veteran Program. Nat Genet 518 2018;50:1514-23. 519 51. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, 520 Venkataraman GR, Wainberg M, Ollila HM, Kiiskinen T, Havulinna AS, Pirruccello JP, et 521 al. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat Genet 2021;53:185-522 94. 523 52. Dev S, Babitt JL. Overview of iron metabolism in health and disease. 524 Hemodialysis international. International Symposium on Home Hemodialysis 2017;21 Suppl 525 1:S6-s20. 526 53. Rafnar T, Gunnarsson B, Stefansson OA, Sulem P, Ingason A, Frigge ML, 527 Stefansdottir L, Sigurdsson JK, Tragante V, Steinthorsdottir V, Styrkarsdottir U, Stacey SN, 528 et al. Variants associating with uterine leiomyoma highlight genetic background shared by 529 various cancers and hormone-related traits. Nature communications 2018;9:3636. 530 54. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, 531 Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, et al. 532 Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility 533 loci. Nat Genet 2018;50:928-36. 534 55. Pendergrass SA, Brown-Gentry K, Dudek SM, Torstenson ES, Ambite JL, Avery 535 CL, Buyske S, Cai C, Fesinmeyer MD, Haiman C, Heiss G, Hindorff LA, et al. The use of 536 phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype 537 relationships and pleiotropy discovery. Genet Epidemiol 2011;35:410-22. 538 56. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid 539 instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 540 2015;44:512-25. 541 57. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, 542 Allen NE. Comparison of sociodemographic and health-related characteristics of UK 543 Biobank participants with those of the general population. Am J Epidemiol 2017;186:1026-544 34. 545 58. Gkatzionis A, Burgess S. Contextualizing selection bias in Mendelian 546 randomization: how bad is it likely to be? Int J Epidemiol 2019;48:691-701. 547

#### 549 Figure legends

550	Figure 1. Manhattan plot showing the phenome-wide association of genetic risk scores of overall
551	(Panel A) and subtypes (Panel B) of ovarian cancer with wide ranges of diseases. Panel C summaries
552	the association of the top 15 signals identified at FDR threshold ( $p = 0.0005$ ) in Panel A or Panel B

- across the different genetic risk scores. The association for the first three diseases (in blue) is a
- validation of the genetic risk scores. Green highlights indicate association that passed the FDR

555 threshold.

- 556 Figure 2. Mendelian randomisation causal estimates between ovarian cancer subtypes and selected
- 557 diseases outcomes. Estimates were from Inverse variance weighted methods. #SNPs are number of
- 558 genetic variants included in the analyses.
- 559 Figure 3. Phenome-wide association findings of ovarian cancer risk-increasing variants, with the
- 560 Manhattan plot showing selected variants associations across all the diseases outcomes (with the y-
- axis showing the level of significance in  $-\log_{10}$  scale), and the forest plot showing the selected variant
- 562 disease associations estimate among women and men.
- 563 **Figure 4.** Colocalisation analysis of ovarian cancer with dermatological condition at the *TERT* locus.
- 564 Panel A. Stacked regional association plots of ovarian cancer and seborrheic keratosis. Panel B.
- 565 Portions of the Posterior probability for full colocalisation (PPFC) explained by each genetic variant
- at the *TERT* locus. The  $r^2$  colour legends reflect the  $r^2$  of each variant with respect to the lead variant.

## 568 Tables

		All, n (%)	Ovarian cancer, n(%)	р
All		181,203	1,863 (1.3)	
				51
Age (in years)	39–49	40,116 (22.2)	231 (0.6)	$1.1 \ge 10^{-51}$
	50–59	62,041 (34.2)	556 (0.9)	
	60–73	79,046 (43.6)	1,076 (1.4)	
Education	None	31.059 (17.1)	421 (1.4)	0.06
	NVO/CSE/A-levels	83.890 (46.3)	819 (1.0)	0.00
	Degree/professional	64.785 (35.8)	607 (0.9)	
	Missing	1,469 (0.8)	16 (1.1)	
BMI (kg/m2)	< 18.5	1.324 (0.7)	10 (0.8)	0.005
	18.5 - <25	70.988 (39.2)	643 (0.9)	
	25 - <30	66.596 (36.8)	713 (1.1)	
	> 30	41,746 (23.0)	489 (1.2)	
	Missing	549 (0.3)	9 (1.5)	
Alcohol				
consumption	Never	7,808 (4.3)	109 (1.4)	0.03
· · · · · · · · · · · · · · · · · · ·	Previous	6,526 (3.6)	64 (1.0)	
	Current	166,747 (92.0)	1,690 (1.0)	
	Missing	122 (0.1)	0 (0.0)	
General health	Excellent	31.630 (17.5)	286 (0.9)	$1.0 \times 10^{-16}$
	Good	109.012 (60.2)	1.041 (1.0)	1.0 10
	Fair	33,519 (18.5)	405 (1.2)	
	Poor	6,431 (3.5)	112 (1.7)	
	Missing	611 (0.3)	19 (3.1)	

### 569 **Table 1.** Prevalence of ovarian cancer by population characteristics

570 p is p-value generated from likelihood ratio test in logistic models adjusted for age, birth

571 location and assessment centers. BMI: body mass index.



# Panel C

			OC	Serous OC	Endometrioid OC	Clear cell OC	Mucinous OC
Disease outcome (Phecode)	Cases,n	Controls,n	Р	Р	Р	Р	Р
Cancer of other female genital organs (184)	2388	122255	4.4E-07	5.2E-05	1.2E-04	2.3E-05	0.04
Malignant neoplasm of ovary and other uterine adnexa (184.1)	2091	122255	2.2E-07	1.7E-04	5.8E-05	3.4E-05	0.05
Malignant neoplasm of ovary (184.11)	2072	122255	1.0E-06	4.8E-04	1.1E-04	4.3E-05	0.04
Secondary malignant neoplasm of digestive systems (198.3)	1084	122255	2.0E-06	4.1E-05	0.009	0.003	0.69
Ascites (572)	845	104686	3.2E-04	0.01	0.007	0.04	0.66
Chronic airway obstruction (496)	5229	146930	1.0E-04	0.002	0.01	0.09	0.86
Abnormal findings examination of lungs (514)	1193	146930	6.9E-05	1.2E-04	0.12	0.07	0.68
Postoperative infection (80)	2153	164159	0.002	0.005	0.005	2.3E-04	0.78
Gram negative septicemia (38.1)	385	164159	0.007	0.007	0.52	3.2E-05	0.81
Benign neoplasm of uterus (218)	9234	122255	0.002	4.4E-04	0.60	1.9E-08	0.72
Uterine leiomyoma (218.1)	9008	122255	0.007	0.001	0.66	3.7E-08	0.93
Disorders of menstruation* (626)	15578	116934	0.03	0.002	0.22	1.5E-04	0.30
Ovarian cyst (628)	4147	116934	6.0E-05	8.9E-04	0.39	1.0E-05	0.92
Lipoma (214)	2636	122255	3.9E-04	0.02	0.04	0.12	0.03
Lipoma of skin and subcutaneous tissue (214.1)	2171	122255	3.7E-05	0.008	0.09	0.08	0.03

#SNPs

OR (95% CI)

Secondary malignant neoplasm of digestive system	ma		
Ovarian cancer (OC)	31		1.64 (1.33, 2.02)
Serves OC	20		134 (117, 155)
Endometrinid OC	- 5		1.82 (1.18.2.81)
Clear Call OC	Ē		1.55 (1.16, 2.06)
Ciear Cell OC	2		1.55 (1.16, 2.06)
Muonous OC	8	_ <b>_</b>	1.02 (0.82, 1.27)
Anciban			
Automa (20)			1 10 11 17 1 000
Ovarian cancer (OC)	31		1.48 (1.17, 1.88)
Serous OC	20	1-1-	1.24 (1.07, 1.45)
Endometrioid OC	5		1.99 (1.06, 3.74)
Clear Cell OC	5		1.40 (1.01, 1.94)
Mucinous OC	8	-	1.04 (0.85, 1.26)
		F	
Change algebra chatmotion		1	
Children an way obtained and		1-	4 47 14 07 4 00
Ovarian cancer (OC)	31		1.17 (1.07, 1.29)
Serous OC	20	=	1.10 (1.03, 1.17)
Endometrioid OC	5	<b>_</b> _	1.29 (1.04, 1.59)
Clear Cell OC	5	+	1.12 (0.97, 1.29)
Mucinous OC	8	+	1.01 (0.94, 1.08)
Abnormal findings examination of lungs			
Overies center (OC)	31		151(122,187)
Reserve OC	20		1.29 (1.00, 1.61)
Cedara do			1.40 (1.08, 1.01)
Endometricid OC	2		1.43 (0.03, 2.43)
Clear Cell OC	2		1.29 (0.95, 1.74)
Mucinous OC	8	-	0.98 (0.84, 1.13)
		1	
Ovarian cyst		1	
Overies center (OC)	31	I	123 (104 146)
Roman OC	20		111 (0.00, 1.36)
Contraction Colo	-0	121	1.11(0.99, 1.25)
Encometricia CC	2		1.11 (0.79, 1.55)
Clear Cell OC	5	1	1.39 (1.08, 1.79)
Mucinous OC	8	-+-	0.99 (0.83, 1.18)
		1	
Lipoma		1	
Overien cencer (OC)	31		124 (102 152)
Servin OC	20		1 13 (0 98, 1 30)
Endometricid OC		1	1 20 /0 80 2 16)
Charles Ord	2		1.20 (0.00, 2.10)
Ciear Cell OC	2		1.16 (0.90, 1.49)
Mucinous OC	8	1 <del>4</del>	1.14 (1.02, 1.27)
Lipoma of skin and subcutaneous tissue		1	
Ovarian cancer (OC)	31	1-8-	1.31 (1.06, 1.61)
Serous OC	20	H.	1.16 (1.00, 1.34)
Endometricit OC	5		1 34 (0 84 2 16)
Clear Call OC	Ē		1 20 40 09 1 47)
Multime 00			1.45 (4.00, 1.47)
Muchous OC	•	-	1.15 (1.03, 1.28)
1 2 1 1 1 2 1 2 1 2 1 1 1 1 1 1 1 1 1 1			
. Postoperative intection			1 00 11 10 1 10
. Ovarian cancer (OC)	31		1.20 (1.10, 1.40)
Serous OC	20		1.15 (1.02, 1.29)
Endometrioid OC	5		= 1.61 (0.93, 2.78)
Clear Cell OC	5		1.47 (1.05, 2.05)
Mucinous OC	8	+	1.00 (0.89, 1.11)
		I	
Oram popation continuaria		1	
· Ovorige seasors (OC)	24		1.65 (1.09, 2.39)
, Orman cancer (OC)			1.00 (1.00, 2.20)
Francisco Co			1.00 (0.00, 1.00)
Endometricid OC	2		1.26 (0.60, 2.62)
, Clear Cell OC	5	L —	2.74 (1.69, 4.45)
Muonous OC	8	_ <b>_</b>	1.05 (0.80, 1.39)
		1	
<ul> <li>Benign neoplasm of uterus</li> </ul>		1	
Overien cencer (OC)	31	+	1.13 (0.95, 1.33)
Serous OC	20	- <b>1</b>	1.09 (0.96, 1.25)
Endometricid OC	5		1.04 (0.66, 1.64)
Clear Call OC	ž.		1.24 (1.00, 1.64)
- Marine CO	3	1	1.34 (1.09, 1.66)
Muchous UC	6	Ŧ	1.01 (0.93, 1.10)
		1	
Uterine leiomyoma		1	
<ul> <li>Ovarian cancer (OC)</li> </ul>	31	+=-	1.11 (0.94, 1.32)
Serous OC	20	+	1.09 (0.96, 1.24)
Endometrioid OC	5		1.03 (0.66, 1.63)
Clear Cell OC	5	<b></b>	134 (108, 166)
' Musiness OC	- -	1	100/0 02 100
, moundar UG	•	Ŧ	1.00 (0.92, 1.09)
1		1	
Disorders of menstruation		1	
. Ovarian cancer (OC)	31	<b>F</b>	1.06 (0.97, 1.16)
<ul> <li>Serous OC</li> </ul>	20	<b>F</b>	1.06 (0.99, 1.13)
Endometrioid OC	5		1.08 (0.91, 1.29)
Clear Cell OC	5	I- <b>-</b> -	1.17 (1.05, 1.31)
Murineus OC		1 · · ·	1.02 (0.96, 1.09)
		· · · · · · · F · · · · · · · · ·	
		1 2	



		Cases.n	Controls.n					OR (95% CI)
								, , , , , , , , , , , , , , , , ,
	Women	10596	115919					0.86 (0.83, 0.90)
	Women	9234	122255				_	1.14 (1.10, 1.18)
	Women	9008	122255				_	1.14 (1.11, 1.18)
	Men	7073	105220					0.88 (0.85, 0.92)
)]	Women	1603	156040		<b>B</b>			0.78 (0.72, 0.85)
	Men	1439	133564			-		0.81 (0.74, 0.88)
	Women	1584	156040		<b>_</b>			0.78 (0.72, 0.85)
	Men	1389	133564					0.79 (0.72, 0.87)
	Women	1110	143687					0.86 (0.79, 0.94)
	Men	1360	117777		<b>_</b>			0.74 (0.69, 0.80)
	Women	217	165527 ——					0.41 (0.34, 0.49)
	Men	444	143918 —	<b>_</b>				0.40 (0.35, 0.45)
	Women Mon	1139 625	104682					1.30 (1.18, 1.42)
	Wen	025	80330					1.10 (0.97, 1.24)
[229]	Women	1397	119457		<b>_</b>			0.79 (0.73, 0.85)
	Men	674	109495		<b>B</b>			0.83 (0.74, 0.92)
	Women	5003	119457			•		0.88 (0.84, 0.91)
	Men	2969	109495			-		0.90 (0.85, 0.95)
459]	Women	7598	114822			-		1.20 (1.16, 1.25)
	Men	9446	86395				<u> </u>	1.15 (1.11, 1.20)
	Women	2199	114822				<b>_</b>	1.30 (1.21, 1.40)
	Men	2707	86395					1.35 (1.27, 1.45)
	Women Mon	7514	114822					1.21 (1.16, 1.26)
r ovtromition [451.2]	Memon	1609	114822				_	1.10 (1.11, 1.20)
r extremities [451.2]	Men	2196	86395					1.52 (1.41, 1.63)
	Women	1535	114822				<b>_</b>	1.44 (1.32, 1.56)
	Men	2056	86395					- 1.55 (1.45, 1.67)
	Mon	11270	112440					1 15 (1 10 1 21)
	wen	11270	112440					1.15 (1.10, 1.21)
	Men	7073	105220		_∎-			0.84 (0.80, 0.87)
87]	Men	3331	111993		∎			0.83 (0.78, 0.87)
87.1]	Men	3086	111993		— <b>—</b>			0.82 (0.78, 0.86)
	Men	3195	111993		— <b>—</b> —			0.82 (0.78, 0.87)
								T

.3

# Ovarian cancer







Phenome-wide association study of ovarian cancer identifies common comorbidities and reveals shared genetics with complex diseases and biomarkers

